FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212838837> ?p ?o ?g. }

• W4212838837 endingPage "2109354" @default.
• W4212838837 startingPage "2109354" @default.
• W4212838837 abstract "The chirality of nanomaterials (nanoparticles, NPs) can influence their interaction with cells and biological systems. However, how chirality can exert impact on the immune response has yet to be investigated. Here, the immunological effect of chiral nanomaterials is investigated as a therapeutic and preventive option against tumors. Compared with achiral nanoparticles, chiral NPs with a g-factor of 0.44 are shown to enhance both innate and acquired immunity against tumor growth. It is also found that chiral NPs enhance the activation of CD8+ T and natural killer cells (CD69+ NK cells) by stimulating dendritic cells (DCs). Importantly, L-type NPs induce a 1.65-fold higher proportion of CD8+ T and CD69+ NK cells than D-type NPs. Next, the therapeutic and preventative effects of chiral NPs against tumors in a EG7.OVA tumor model are investigated. It is found that L-type NPs have a significant greater ability to induce apoptosis in tumor cells and prolong the survival time of model mice than D-type NPs. Mice treated with L-type NPs induce the activation of 84.98 ± 6.63% CD8+ T cells and 33.62 ± 3.41% of NK cells in tumor tissues; these are 1.62-fold and 1.39-fold higher than that seen in the mice treated with D-type NPs. Mechanistic studies reveal that chiral NPs exert mechanical force on bone-marrow-derived dendritic cells (BMDCs) and stimulate the expression of cytokines to induce cytotoxic activity in NK cells. Synergistically, the CD8+ T cells are stimulated to eliminate tumor cells via antigen cross presentation. The force of interaction between L-type NPs and cells is higher than that for D-NPs, thus further promoting the activation of NK cells and CD8+ T cells and their infiltration into tumor tissue. These findings open up a new avenue for chiral nanomaterials to act as immunoadjuvants for the prevention and treatment of cancer." @default.
• W4212838837 created "2022-02-24" @default.
• W4212838837 creator A5003905346 @default.
• W4212838837 creator A5004303362 @default.
• W4212838837 creator A5010607811 @default.
• W4212838837 creator A5013544818 @default.
• W4212838837 creator A5023884643 @default.
• W4212838837 creator A5038600513 @default.
• W4212838837 creator A5042726750 @default.
• W4212838837 creator A5043524890 @default.
• W4212838837 creator A5056891933 @default.
• W4212838837 creator A5063253432 @default.
• W4212838837 creator A5089695285 @default.
• W4212838837 date "2022-03-10" @default.
• W4212838837 modified "2023-10-10" @default.
• W4212838837 title "The Development of Chiral Nanoparticles to Target NK Cells and CD8 ⁺ T Cells for Cancer Immunotherapy" @default.
• W4212838837 cites W1969950463 @default.
• W4212838837 cites W2124951764 @default.
• W4212838837 cites W2559416056 @default.
• W4212838837 cites W2576658154 @default.
• W4212838837 cites W2597613988 @default.
• W4212838837 cites W2606608340 @default.
• W4212838837 cites W2728365508 @default.
• W4212838837 cites W2750781282 @default.
• W4212838837 cites W2768778626 @default.
• W4212838837 cites W2769095299 @default.
• W4212838837 cites W2782472870 @default.
• W4212838837 cites W2795245284 @default.
• W4212838837 cites W2800103955 @default.
• W4212838837 cites W2801287827 @default.
• W4212838837 cites W2890499629 @default.
• W4212838837 cites W2894609651 @default.
• W4212838837 cites W2896470465 @default.
• W4212838837 cites W2905296697 @default.
• W4212838837 cites W2911761965 @default.
• W4212838837 cites W2952233665 @default.
• W4212838837 cites W2958502160 @default.
• W4212838837 cites W2982245165 @default.
• W4212838837 cites W2983715387 @default.
• W4212838837 cites W2987501378 @default.
• W4212838837 cites W2998314570 @default.
• W4212838837 cites W2998493318 @default.
• W4212838837 cites W2999754525 @default.
• W4212838837 cites W3003773438 @default.
• W4212838837 cites W3006101076 @default.
• W4212838837 cites W3006551181 @default.
• W4212838837 cites W3009514857 @default.
• W4212838837 cites W3014387873 @default.
• W4212838837 cites W3017086477 @default.
• W4212838837 cites W3026910902 @default.
• W4212838837 cites W3028523516 @default.
• W4212838837 cites W3031986878 @default.
• W4212838837 cites W3037638848 @default.
• W4212838837 cites W3037919768 @default.
• W4212838837 cites W3039484069 @default.
• W4212838837 cites W3039693333 @default.
• W4212838837 cites W3047434669 @default.
• W4212838837 cites W3048735984 @default.
• W4212838837 cites W3080399909 @default.
• W4212838837 cites W3088242221 @default.
• W4212838837 cites W3092269818 @default.
• W4212838837 cites W3093695186 @default.
• W4212838837 cites W3094151083 @default.
• W4212838837 cites W3096524591 @default.
• W4212838837 cites W3096886301 @default.
• W4212838837 cites W3111589283 @default.
• W4212838837 cites W3112311946 @default.
• W4212838837 cites W3131861897 @default.
• W4212838837 cites W3134443156 @default.
• W4212838837 cites W3142424589 @default.
• W4212838837 cites W3157425701 @default.
• W4212838837 cites W3165951116 @default.
• W4212838837 cites W3182299100 @default.
• W4212838837 cites W3185603121 @default.
• W4212838837 cites W3203524141 @default.
• W4212838837 cites W4206202563 @default.
• W4212838837 doi "https://doi.org/10.1002/adma.202109354" @default.
• W4212838837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35176181" @default.
• W4212838837 hasPublicationYear "2022" @default.
• W4212838837 type Work @default.
• W4212838837 citedByCount "28" @default.
• W4212838837 countsByYear W42128388372022 @default.
• W4212838837 countsByYear W42128388372023 @default.
• W4212838837 crossrefType "journal-article" @default.
• W4212838837 hasAuthorship W4212838837A5003905346 @default.
• W4212838837 hasAuthorship W4212838837A5004303362 @default.
• W4212838837 hasAuthorship W4212838837A5010607811 @default.
• W4212838837 hasAuthorship W4212838837A5013544818 @default.
• W4212838837 hasAuthorship W4212838837A5023884643 @default.
• W4212838837 hasAuthorship W4212838837A5038600513 @default.
• W4212838837 hasAuthorship W4212838837A5042726750 @default.
• W4212838837 hasAuthorship W4212838837A5043524890 @default.
• W4212838837 hasAuthorship W4212838837A5056891933 @default.
• W4212838837 hasAuthorship W4212838837A5063253432 @default.
• W4212838837 hasAuthorship W4212838837A5089695285 @default.
• W4212838837 hasConcept C149532602 @default.
• W4212838837 hasConcept C154317977 @default.
• W4212838837 hasConcept C167672396 @default.

• next